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Review
Uncovering Enhancer Functions Using the a-Globin
Locus
Douglas Vernimmen*
The Roslin Institute, Developmental Biology Division, University of Edinburgh, Easter Bush, Midlothian, United Kingdom
Abstract: Over the last three decades, studies of the a-
and b-globin genes clusters have led to elucidation of the
general principles of mammalian gene regulation, such as
RNA stability, termination of transcription, and, more
importantly, the identification of remote regulatory
elements. More recently, detailed studies of a-globin
regulation, using both mouse and human loci, allowed
the dissection of the sequential order in which transcrip-
tion factors are recruited to the locus during lineage
specification. These studies demonstrated the importance
of the remote regulatory elements in the recruitment of
RNA polymerase II (PolII) together with their role in the
generation of intrachromosomal loops within the locus
and the removal of polycomb complexes during differ-
entiation. The multiple roles attributed to remote
regulatory elements that have emerged from these
studies will be discussed.
Introduction
Developmentally regulated genes become activated only in the
appropriate lineage, while they remain inactivated (or become
fully repressed) in other lineages. Haematopoiesis offers an
excellent system to study gene regulation because it is very
accessible and produces a palette of a least eight different lineages
in the blood [1]. Also, differentiated cells and their progenitors can
be easily separated and purified using different cell surface markers
[2,3]. The erythroid cell lineage is of particular interest because of
the high expression level of the globin genes, which produce the
major proteins found in red blood cells. Adult haemoglobin (HbA)
is made by the formation of a tetramer containing two a-globin
chains and two b-globin chains. The level of expression of these
proteins needs to be equimolar to ensure the correct formation of
this tetramer; an imbalance would create insoluble homotetra-
mers, the key pathological feature of thalassaemia [4].
The expression of adult a- and b-globin genes requires a panel
of different tissue-specific transcription factors (TFs), including
GATA1, GATA2, nuclear factor-erythroid 2 (NF-E2), stem cell
leukaemia factor (SCL), and Kru¨ppel-like factor 1 (KLF1)
(formerly called Erythroid Kru¨ppel-like factor [EKLF]). These
TFs are expressed at different times during differentiation,
suggesting specific roles for each [5]. For example, GATA2 is
expressed early, in common myeloid progenitors, whereas GATA1
is expressed later, in erythroid progenitors. KLF1 is also expressed
late during erythroid differentiation and therefore is important for
late events in erythropoiesis such as the expression of the a- and b-
globin genes [6,7].
Enhancers were originally defined as sequences that increase the
rate of transcription of a target gene [8–10]. They may lie far away
upstream or downstream from the gene they regulate [10] and
should work in both orientations [11]. These original definitions
were based on reporter assays (i.e., plasmids) in which the distance
separating enhancers and promoters is very small and the
chromatin context is not taken into account. The activity in both
orientations was primarily due to the fact that simple enhancers
were identified as regions formed by a palindromic sequence (e.g.,
binding site of a homodimer [12]). It became more obvious later
that enhancers usually work in groups (i.e., locus control region
(LCR) and super enhancers [13]), each being bound by several
TFs, forming a so-called enhanceosome [14,15]. These enhanceo-
somes are nucleated by pioneer TFs early during differentiation
and subsequently are replaced by other TFs that trigger
transcription by PolII recruitment. More recently, in vivo studies
found that enhancers (remote regulatory elements) can be located
sometimes up to 1 Mb away from the gene they regulate [16–18].
What do these sequences do? How do they function across very
large distances? These have been questions of major interest over
the last two decades. Studies on the a- or b-globin loci have been
pioneers in this field, and many approaches and tools have been
developed to address this.
Overall, three main strategies have been used to understand the
molecular mechanisms involved in the activation of the globin
genes. The first involves biochemistry and molecular biology using
different cell types representing different stages of differentiation
and the analysis of TF complexes, TF binding patterns,
chromosome conformation, and epigenetic changes. The second
involves mouse genetics, and the third strategy involves the study
of patients carrying different types of mutations (in these cases
deletions) associated with the downregulation of expression of
globin genes leading to thalassaemia. This review will be focused
on studies made on both the mouse and the human a-globin loci
and more particularly on the role attributed to the remote
regulatory elements controlling their expression.
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Structure of the a-Globin Locus
Studies of both the mouse and the human a-globin loci offer
complementary advantages. The mouse locus can be manipulated
easily, and the repertoire of cell lines is greater, whereas the
human locus can be studied in samples obtained from patients [4].
The a-globin locus of all mammalian species analysed lies within a
region of 135–155 kb of conserved synteny, with the a-like genes
arranged along the chromosome in the order 59-f-a-a-39
(Figure 1) [19]. However, the mouse and human loci also show
some important structural differences. The mouse locus has an
arrangement containing two pseudogenes h (59-f-a1-59h-a2-39h-
39, Figure 1), whereas the human has an arrangement containing
only one pseudogene h, with another pseudogene (aD) that
precedes the adult a genes (59-f-aD-a2-a1-h-39). The aD gene is
expressed in erythroid cells [20]. Also, the human a-like genes are
each covered by a CpG island (Figure 1), which has a strong
influence on their regulation (see below). The erythroid-specific
multispecies conserved sequences (MCS) identified by DNase
hypersensitive sites (DHS) have been numbered MCS-R1 to
MCS-R4 [19] (Figure 1). Three of these elements (MCS-R1,
MCS-R2, and MCS-R3) lie within the body of a housekeeping
gene, NPRL3, and MCS-R4 lies upstream of the promoter of that
gene (Figure 1). However, the mouse locus contains an additional
DHS, located 12 kb upstream of the f gene (HS –12), that appears
to be important during the priming of the locus during
differentiation [5].
The globin gene disorders (haemoglobinopathies), including
thalassaemias, are among the most common human genetic
diseases, with more than 300,000 severely affected individuals
born throughout the world every year [21]. Thalassaemias are
characterized by inherited mutations leading to a reduction of the
synthesis of a- (a-thalassaemia) or b-globin (b-thalassaemia) chains
from one allele. Human genetics is a good approach to identify
functional remote regulatory elements, and original observations
were made in patients with a- and b-thalassaemia [22–24]. In
most cases, a deletion removing a globin gene is the cause of this
down-regulation, but in some rare cases, the genes (including their
promoters) remain intact [25].
In rare cases of a-thalassaemia, further chromosome mapping
in a number of patients led to the identification of other deletions
located far upstream, overlapping the NPRL3 housekeeping gene
[26] and therefore the remote erythroid hypersensitive sites
(Figure 1). By comparing all the different deletions in the NPRL3
gene, it appears that MCS-R1 and MCS-R2 are consistently
removed in all cases, and this led to the characterisation of these
sequences [27,28]. From these observations, different approaches,
such as transient transfections and transgenics, have showed that
MCS-R2 (previously called HS –40) has a much stronger
enhancer activity. Moreover, this element shows a remarkable
Figure 1. The chromosomal organisation of the mouse (top) and human (bottom) a-globin clusters. The embryonic f gene in each locus
is represented in yellow, the pseudogenes in purple, and the foetal/adult a genes in red boxes. The positions of DNase I hypersensitive sites,
discussed in the text, are shown as arrows. The widely expressed gene NPRL3 is transcribed from the opposite strand to that of a-globin and is shown
as an orange box, with exons in black bars. Grey boxes refer to previously defined multispecies conserved elements (MCS), and light-green boxes
indicate CpG islands. Note the lack of CpG islands in the mouse locus. The previously described natural (IJ, MC) and targeted (C40, DMCS-R2)
deletions from the human and targeted deletions from the mouse (DP6, DP6-R3, and SND) a-globin cluster are shown as annotated.
doi:10.1371/journal.pgen.1004668.g001
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conservation throughout evolution. In zebrafish, it already lies in
the intron of the NPRL3 gene and drives the expression of both a-
and b-globin on the same locus through a bidirectional promoter,
securing comparable levels of a- and b-like globin protein [29].
The globin locus in fish has then diverged over time and
segregated into separate a and b loci after the divergence of
amphibians 450 million years ago, leaving the ancestral globin
locus as an a-globin locus [30,31]. Therefore, further efforts were
concentrated on the characterisation of the ancestral MCS-R2
element in detail [28,32–34].
Epigenetic Control of a-globin Gene Expression
The epigenetic programme seems to play a key role in
determining cell fate, including the decision to undergo self-
renewal or commitment. Chromatin immunoprecipitation (ChIP)
followed by high-throughput sequencing (ChIP-Seq) studies have
suggested that the chromatin associated with many genes
controlling lineage fate decisions is uniquely marked in stem cells
[35]. Their histone signature includes modifications associated
with both transcriptional repression (H3K27me3) imposed by the
polycomb group proteins (PcG) and activation (H3K4me3)
mediated by the trithorax group proteins (TrxG) [36]. The
‘‘permissive’’ chromatin state of these genes in stem cells is called
bivalent and is supposed to be resolved during differentiation, as
genes become fully activated or repressed [37–39]. The recruit-
ment of complexes such as PcG and TrxG involves the presence of
a CpG island at the target promoter of a developmentally
regulated gene, and proteins with a CXXC domain binding to the
DNA [40–44]. The maintenance and propagation of an epigenetic
mark, such as H3K27me3 by polycomb repressive complex 2
(PRC2), is well documented and involves a ‘‘reader’’ protein
(EDD), which recognises a modified histone, and a ‘‘writer’’
protein (histone methyltransferase Ezh2), which modifies the
histones nearby [45]. The removal of such a mark by an ‘‘eraser’’
protein (histone demethylases JMJD3 and UTX) would prevent
the maintenance and propagation from occurring. The human a-
globin genes are associated with a CpG island, whereas in rodents
(e.g., mouse and rat) this CpG island has been lost during
evolution (Figure 1) [43]. Therefore, the presence of a CpG island
on the human locus has an important implication in the epigenetic
regulation of that locus (see below).
In mouse embryonic stem (ES) cells, the analysis of the mouse a-
globin locus initially suggested it to be unmarked by any histone
modifications such as H4ac or H3K4me2 [5]. More recent
genome-wide studies (ChIP Seq) have shown that in ES cells,
remote regulatory elements of a small number of developmentally
regulated genes are already marked by H3K4me1, and in the
mouse a-globin locus, a deposition of H3K4me1 has been found
just next to MCS-R1 (HS –31) in ES cells [46], suggesting a
possible priming around that region.
In human ES cells and in nonerythroid cells, the CpG island is
associated with PRC2 recruitment and its associated signature
(H3K27me3), whereas these are not found in the rodent a-globin
genes [47]. In human ES cells, the a-globin CpG islands are also
covered by H3K4me3. However, the domains of H3K27me3 and
H3K4me3 do not entirely overlap, and the ratio observed
progressively changes during differentiation [48], suggesting that
the progressive increase of H3K4me3 could be due to an
expression of the gene at irrelevant stages rather than a signature
of priming, as suggested by previous studies [36,49]. Therefore,
single-cell mRNA expression in human ES cells was measured and
revealed that although full length a-globin mRNA was detected in
a small number of Oct4 positive cells, this number increased
during differentiation. This suggested that some bivalent domains
might be the consequence of a subpopulation phenomenon rather
than true priming in all cells [48]. PcG complexes remain until the
last stages of differentiation [48].
Locus Priming during Differentiation
Developmentally regulated genes are progressively primed
during the differentiation programme, a process that involves the
sequential recruitment of stage-specific TFs associated with histone
modifications. The study of a-globin was initiated using the mouse
locus and a panel of different cell lines and primary cells that
represent the different stages of erythroid differentiation (Figure 2)
[5]. As a source of multipotent cells, mouse ES cells have been
used, and so far no TFs have been found bound within the mouse
a-globin MCS-Rs. This contrasts with other single-locus studies
such as the mouse b-globin locus [50] and the l5-VpreB1 locus
[51] showing priming at enhancers (including PolII recruitment) in
ES cells, long before transcription occurs (differentiated erythroid
and B cells, respectively).
As a source of common myeloid progenitor cells (CMP), factor
dependent cell Patterson (FDCP)–mix cells have been used [52].
These are able to produce both megakaryocytic and erythroid
lineages. In these cells, the mouse a-globin locus is primed at
MCS-R2 and HS –12 by GATA2 (Figure 2B) [5]. During
differentiation, GATA2 regulates the expression of GATA1 with
a negative feedback loop, which shuts down GATA2 expression in
proerythroblasts [53]. As a source of proerythroblasts, the MEL
(mouse erythroleukemia) cell line has been used. This cell line was
originally transformed by the Friend virus [54] and is a very useful
model to study the last stages of erythroid differentiation since, like
most blood cell lines, it can be induced towards terminal
differentiation after exposure to certain chemicals. Under treat-
ment with inducing agents, such as dimethyl sulphoxide (DMSO)
or hexa-methylene bis-acetamide (HMBA), MEL cells turn a red
colour because of haemoglobinisation. At the proerythroblast stage
(uninduced MEL), most remote regulatory elements are formed
(HS –12, MCS-R1, MCS-R2, and MCS-R4) with the recruitment
of key erythroid TFs, including GATA1, NF-E2 (dimer p45 and
p18), and the SCL pentameric complex (Figure 2C) [5]. The
promoter also becomes accessible and bound by GATA1, 89-kDa
zinc finger protein (ZBP-89), and nuclear factor Y (NFY) (CAAT-
box-binding protein). The human a-globin promoter does not
contain an evolutionarily conserved GATA site and does not bind
ZBP-89, but NFY binding is common in both species [7]. NFY has
a histone-like structure [55] and therefore could be involved in
chromatin opening by nucleosome replacement [56]. In erythro-
blasts (induced MEL), more changes occur, with the appearance of
MCS-R3 (HS –21), together with recruitment of KLF1 (Fig-
ure 2D) and the preinitiation complex (PIC) at both enhancers
and promoters in the human and the mouse a-globin loci
(Figure 2E) [7]. At that final stage, other Sp/X-Kruppel-like
transcription factors (Sp/X-KLFs) are also recruited to the a-
globin promoters [57,7]. Interestingly, a looped structure that
bridges the remote regulatory elements to the promoter was also
detected by chromosome conformation capture analysis using
quantitative Taqman technology (q3C) at that particular stage of
differentiation (Figure 2F) [7], where high level of a-globin
expression occurs. NPRL3 gene expression is also up-regulated
in human [58] and mouse [59] erythroid cells and associated with
bidirectional intergenic transcripts at these elements (enhancer
RNA [eRNA]) [59]. The more recent advances of ChIP-Seq
technologies allowed other groups to find the same phenomenon
with peaks of PolII in intergenic regions [60–62] associated with
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H3K4me1, a key feature of enhancers [63]. Note that the
characterization of the human a-globin locus in progenitor cells
has not been characterized to the same depth as in differentiated
cells because the repertoire of progenitor cells is less accessible.
Indeed, progenitor cells can be obtained from bone marrow
samples from individuals undergoing total hip replacement for
osteoarthritis [48] or after mobilisation for bone marrow
transplant, but the amount of cells collected is still very limited.
Role(s) of the Remote Regulatory Sequences
The natural deletions observed in patients were an essential tool
in the analysis of the role of these remote regulatory elements. Due
to the nature of the disease (anaemia), it was however difficult to
perform a number of experiments on primary cells because of the
large amount of material required and also because this material is
only available for a limited time. For this reason, interspecific
hybrids were produced by the fusion of a human immortalised B
cell (Epstein-Barr virus [EBV] infected) with the mouse MEL cell
line described earlier [24,28,64,65].
Therefore, interspecific hybrids, derived from normal individ-
uals or those with previously characterised natural mutations of
the a-globin cluster, were analysed to determine if the PIC was
recruited independently both at the promoter and at the remote
regulatory elements. Two types of mutation were analysed: one in
which the remote upstream elements had been fully (IJ) deleted
but the a promoters remained intact [27,66] and another in which
all a-like genes were deleted (MC) but the upstream elements were
Figure 2. Model showing sequential order of TF binding on the mouse a-globin locus during erythropoiesis. The locus has been
analysed in pluripotent cells (A), myeloid progenitors (B), committed erythroid progenitors (C), and in differentiating erythroid cells (D, E, F). Note that
D, E, and F do not represent different steps during activation but simply separate illustrations representing the formation of MCS-R3 and recruitment
of KLF1 (D), the recruitment of PolII at the enhancers independently of the promoter (E), and a multilooped structure involving enhancers and
promoters (F). Note that the human a-globin locus has been mainly characterised in human ES cells and primary erythroid cells. It is still not known if
MCS-R2 is also primed in human progenitor cells (i.e., myeloid progenitors) as it is for the mouse locus. Studies have shown that the TF binding
pattern is essentially the same with two main key differences: GATA1 does not bind the human promoter in erythroid cells, and the gene is repressed
by PcG complexes in human ES cells. PcG complexes are removed late during erythropoiesis. For the sake of clarity, the locus has been represented as
a double helix of DNA rather than by a 10 nm chromatin fibre.
doi:10.1371/journal.pgen.1004668.g002
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still present (Figure 1). From these studies, two important
principles in the hierarchy governing the process of transcription
activation have been uncovered. First, the presence of the remote
enhancers is required for the recruitment of the PolII at the
promoter. Secondly, the presence of the promoter is not required
for PolII recruitment at the enhancers [7]. In other words, the
recruitment of PolII at the enhancers occurs independently of
the promoter. In a similar way, preventing PolII recruitment at the
mouse b-globin promoter does not affect its binding at the
upstream LCR [67]. This important feature was validated later on
a study on the Arc locus [61] where, in the Arc gene knockout
neurons, PolII remains bound at the Arc enhancer at levels
equivalent to those observed in wild-type neurons. In the former
study, eRNA synthesis is abolished in the absence of the gene,
suggesting that, like mRNA synthesis, eRNA synthesis may require
an interaction of the enhancer with a promoter [61]. However,
another study on the human growth hormone (hGH-N) locus
showed that this is not always the case [68].
The use of interspecific hybrids is a useful way to study
enhancer functions; however, they are very difficult to maintain,
mainly because they tend to lose the human chromosome 16 and
they are still also very difficult to induce into erythroblasts. More
recently, another mouse model was generated in which the whole
region of conserved synteny (87 kb of mouse genomic DNA) was
replaced by the human orthologous region (117 kb of human
genomic DNA) [69]. Therefore, a humanized mouse was
produced, which offers the advantage to avoid the issues generated
by the use of conventional transgenics [69,70]. Although the
spatiotemporal expression of the human a-globin was correct, the
level seemed to be suboptimal at about 50% of what was expected.
However, in this model, the pattern of TF binding (including
PolII) and the looped structure seem to be identical to that in
human primary erythroblasts [71,72]. This new model was
therefore the best one to use so far to investigate the role of
MCS-R2. A deletion of about 1.1 kb covering MCS-R2 was made
in heterozygous mice (one humanised chromosome and one
normal mouse chromosome). In this situation, the level of a-globin
expression reached only,2% compared to the normal humanised
chromosome [69,71]. These data recapitulated well the previous
data obtained with other models, including a hybrid clone bearing
the same deletion (Figure 1, C40 hybrid [27]).
The changes of TF binding and chromosomal looping were
then analysed in normal humanised mice and compared to
humanized mice without MCS-R2 (DMCS-R2) [73]. In the
DMCS-R2 mutant, the absence of a-globin expression is
associated with a lack of PolII binding together with an impaired
looping formation. The occupancy of PolII from the start to the
end of the gene is about 6%–3% of normal, matching the amount
of mRNA expressed, and therefore ruled out any role of MCS-R2
in PolII elongation. A role in PolII elongation was originally
suggested for the LCR of the b-globin locus [74]. In this study, a
targeted deletion of the human LCR in transgenic mice reduces
PIC recruitment of about 50% to normal but with a more
dramatic effect on Ser5 phosphorylation of PolII (Ser-5P) and
transcriptional elongation, suggesting a role for the b-globin LCR
in both PolII recruitment (partially) and elongation. Similar
observations were made later with the mouse b-globin locus, in
which a targeted deletion of the mouse LCR reduces global PolII
recruitment at the promoter to 30% of normal with a redistribu-
tion of Ser-2P along the gene [75]. Recently, the Furlong group
showed that in Drosophila enhancers would loop towards a target
promoter to recruit PolII but paused in the majority of cases.
Releasing of PolII pausing would then occur by subsequent
recruitment of additional TFs or additional enhancers [76]. Note
that in the studies of the a-globin locus, kinases regulating PolII
such as cdk7 (TFIIH), cdk-8 (mediator), and cdk9 (elongation
factor p-TEFb) are all recruited at the same time on the promoter
when looping and transcription occur [7]. On the mouse b-globin
locus, cdk9 and PolII Ser-2P binding is observed at both the LCR
and the promoter when the gene is active [75]. Although the
binding of cdk9 to the LCR precedes its binding to the promoter,
the deletion of the LCR does not affect cdk9 binding at the
promoter. This study would suggest that the b-globin LCR may
not control elongation by delivery of cdk9 but would involve other
complexes such as DRB sensitivity inducing factor (DSIF) and
facilitates chromatin transcription (FACT) [77]. Another study on
the Myb locus in erythroid cells [78] together with a genome-wide
study in human B lymphoblast cells (MM1.S) [79] suggested an
important role of cdk9 bound to enhancers. Other genome-wide
studies detected one (Ser-5P) [60] or both (Ser-2P and Ser-5P) [80]
phosphorylated forms of PolII at active enhancers, supporting the
idea that enhancers would deliver an activated PolII at the target
promoters. A general role of remote enhancers in PolII delivery to
a target promoter has been also described in other loci such as the
human growth hormone (hGH) locus [81,82], the human serpin
cluster [83], and the mouse T cell receptor beta (TCRb) locus
[84].
In the DMCS-R2 mutant, the PolII occupancy at the other
remaining enhancers is also affected but not as much as at the
promoter. In fact, the MCS-R1 element, located upstream of the
deletion, is less affected (,20% of normal PolII occupancy) than
the other regions downstream (MCS-R3, MCS-R4, and the
promoter). The same trend is observed with other components of
the PIC and other TFs such as KLF1 (Figure 3) [73]. Strikingly,
this same observation was previously made with the C40 hybrid,
albeit with a less dramatic reduction of TF binding (general
transcription factors [GTFs] are unchanged at MCS-R1, and PolII
occupancy level at the promoter is of about 20% compared to
normal; [7], see discussion below). This reduction of TF
occupancy across the locus suggests that the activating signal is
propagating from the upstream elements towards the downstream
promoter. The nature of this signal polarity is not yet understood
and still has to be tested experimentally. Note, a polarity has been
shown with the b-globin LCR locus, which works in an
orientation-dependent manner [85]. Although this could also
suggest a form of facilitated tracking, involving a unidirectional
(multi)looped structure progressing towards the downstream
promoters [86–89], there was no evidence of TF binding in the
intervening DNA regions. Keeping this idea in mind, MCS-R2
was reinserted in an ectopic site in the region of conserved synteny,
just downstream from the a-globin genes (Figure 4) [71]. In this
new mutant (39 MCS-R2), transcription is reactivated to about
,50%, and more importantly, the looped structure is reestab-
lished. This would argue against a facilitated-tracking model since,
in this situation, the other remote elements (MCS-R1, MCS-R3,
and MCS-R4) interact again with MCS-R2 and the a-globin
genes, both located on the other side of the loop (Figure 4).
The analysis of MCS-R2 was completed by investigating its
potential role in the deposition and/or removal of histone
modifications, which are associated with activation and repression.
Since the literature has reported about 150 possible histone
modifications [90], this a-globin study concentrated on the main
modifications associated with activation (H3 and H4 acetylation,
H2B ubiquitination, H3K79me3, H3K4me3, and H3K36me3)
and repression (H3K27me3). Repression associated with poly-
comb repressive complex 1 (PRC1) was not investigated because of
the poor efficiency of the antibodies against PRC1 proteins and
their associated modification (H2Aub). In agreement with the very
PLOS Genetics | www.plosgenetics.org 5 October 2014 | Volume 10 | Issue 10 | e1004668
low expression of the gene without MCS-R2, modifications such as
H2Bub and H3K79me3 do not occur. Histone 3 mono- and di-
methyl K79 are less affected by the deletion and are also found at
the other remote regulatory sequences, whereas H3K79me3 was
exclusively found at the body of the gene. Surprisingly, all
modifications generated by the TrxG pathway (H3K4me1,
H3K4me2 and H3K4me3) occur normally in the absence of
MCS-R2. Histone 3 tri-methyl K4 is, however, suboptimal at the
Figure 3. Differential occupancy of TFs in the absence of the enhancer (MCS-R2) in mouse primary erythroblasts. The percentages of
occupancy in the mutant human allele (DMCS-R2) was calculated by comparison with the normal human allele ( = 100%) after normalising the ChIP
efficiency to an endogenous control (mouse a-globin allele). This graph shows a reduction of TFs occupancy (59R39) with the distance along the
locus, with the lowest occupancy observed at the gene (Pr/Ex1 – Ex2 – Ex3). Figure adapted from Vernimmen et al., 2011; Genes and Development
[73].
doi:10.1371/journal.pgen.1004668.g003
Figure 4. Communications between enhancers influences transcription. Intrachromosomal interactions involving human remote regulatory
sequences and the human a-globin genes in normal, DMCS-R2, and 39MCS-R2 humanised alleles in mouse primary erythroblasts.
doi:10.1371/journal.pgen.1004668.g004
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body of the gene, and H3K4me1 is not only detected at the other
MCS-R but is also significantly enriched at the body of the gene. It
is worth noting that these are both common features observed in
ES cells [48].
It was originally thought that the generation of H3K4me3 in
DMCS-R2 mutant is due to the presence of the CpG island, since
it was previously reported that the a-globin genes were already
covered by this activating mark in human ES cells [47]. Moreover,
the work from Adrian Bird’s group has shown that a CXXC
domain protein, cfp1 (also called CpG binding protein [CGBP]) is
involved in the deposition of H3K4me3 at the CpG island of
target genes regardless of their transcription status [44]. CGBP is
part of a TrxG complex (human Set1) and therefore would
generate H3K4me3 at any CpG island. In ChIP analysis, CGBP is
only detected at the a-globin CpG island in the presence of MCS-
R2 [73], suggesting another mechanism for H3K4me3 deposition
in DMCS-R2 mutant. It was also reported that the binding of
CGBP could be mutually exclusive with other proteins binding to
CpG islands such as PcG [44]. Indeed, in the absence of MCS-R2,
PRC2 (including histone deacetylase 1 [HDAC1]) recruitment
continues at the a-globin CpG island throughout the whole
process of erythroid differentiation, whereas this complex is
removed in the presence of MCS-R2 enhancer (Figure 5).
Importantly, the removal of PRC2 and H3K27me3 was associated
with the recruitment of the H3K27me3 demethylase JMJD3 at the
CpG island [73].
Conclusions
Using a-globin as a model, the study of enhancer biology was
made possible by using cell lines and primary cells that faithfully
represent the different stages of erythropoiesis. The sequential
order of TF binding, with the appearance of DHSs, is followed by
the recruitment of PolII at both enhancers and promoter at the last
stages of erythropoiesis, when globin expression occurs. This
contrasts with studies on the mouse b-globin and the l5-VpreB1
loci in which PolII is also recruited late at the promoter but is
detected very early at the remote regulatory elements [50,51].
Using human genetics, it has been possible to show that the
recruitment of PolII at the remote enhancers occurs independently
of the promoter. The general idea that enhancers act as docking
sites for the recruitment of the general transcription machinery
(components of the PIC and not just PolII) has been suggested in a
few studies [60,91,92].
Once the PIC is recruited to the enhancer, this transcription
machinery would be then somehow transferred to the downstream
promoter by a looping mechanism. Note that although the
duplicated a-globin genes in most species have similar or identical
Figure 5. Multiple roles of enhancers. Enhancers (E) work in groups. They recruit PIC and TFs and interact with each other (1), which is associated
with increased PolII concentration and production of eRNA. Enhancers subsequently deliver the PIC to a target promoter (P) through a looped
structure (2). They control transcription elongation of some genes (e.g., by delivering an important kinase such as cdk9) by increasing the
phosphorylation of PolII (3). They remove PcG repressive complexes from CpG islands of developmentally regulated genes through a histone
demethylase (e.g., JMJD3) removing H3K27me3 (4).
doi:10.1371/journal.pgen.1004668.g005
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promoters, the gene closest to the upstream elements is usually
expressed at the higher level (reviewed in [93]). When more than
two genes are present, the additional genes lying downstream
appear to be expressed at even further decreased levels [94] and
thus suggest the possibility of a local tracking process involved.
However, this would be unlikely since the terminator element of
the first gene should block this tracking [81], and the second gene
(in the mouse) is flanked by CTCF [95], which should also block
such a tracking mechanism [87]. By using both samples from
patients and humanised mice bearing a deletion covering the
major remote element (MCS-R2), it has been possible to show that
the enhancer is required for the recruitment of the PIC and key
TFs at the promoter. How the PIC is recruited to enhancers is still
not known. An in vitro study on the b-globin locus suggested that
TFs bound to enhancers are able to recruit directly the PIC [96],
but in vivo studies on the same locus suggest that the b-globin
LCR facilitates the localisation of the locus in active transcription
sites termed transcription factories [77]. Both the a- and b-globin
loci are associated with active transcription sites in the nucleus of
living cells [97], but it is still left to debate if these transcription
factories are simply reflecting focal accumulations of PolII on
transcribing genes or preassembled organising structures to which
genes move (reviewed in [98]).
Developmentally regulated genes are controlled by several
enhancers, recently termed super enhancers [99], and q3C
analysis showed that a-globin enhancers also communicate with
each other (Figure 2E and Figure 4) [71]. These enhancers are
primed at different times during differentiation, and this might
create a sort of directionality of the signal. Interestingly, the
deletion of MCS-R2 creates a reduction of TF binding
downstream, across the locus (Figure 3) [73]. This could be the
result of an impaired multilooped structure involving all the
enhancers and the two a-globin promoters together. What ties the
loop on the a-globin locus still has to be determined. Many
proteins involved in the interactions between enhancers and
promoters have been described (reviewed in [100]), and the role of
each on the a-globin locus still has to be investigated.
CpG islands were originally found in housekeeping genes and
are involved in keeping the chromatin open and therefore allowing
basic transcription to occur [101]. However, we now know that
CpG islands are also found in the promoters of developmentally
regulated genes, which are not always active. For this group of
CpG island promoters, PcG act to block the promoter accessibility
in inappropriate lineages or at other stages during the differen-
tiation programme. Nevertheless, it is not clear why developmen-
tally regulated genes should have CpG islands in the first instance.
In stem cells, the level of H3K4me3 observed at the human a-
globin gene is indeed associated with full-length transcripts, albeit
at a very low level [48]. The mouse a globin seems to be perfectly
regulated in the absence of a CpG island. Although the level of
full-length transcripts increases together with H3K4me3 during
differentiation, H3K27me3 and PcG complexes seem to remain
until the last stage of differentiation. The humanised mouse model
made it possible to show that the removal of this repressive mark
was dependent on the MCS-R2 enhancer, together with the
recruitment of demetylase JMJD3 [73]. Of interest, another
mutant with MCS-R2 deletion (C40 hybrid) did not show any
persistence of PcG at the a-globin gene (unpublished data). This
deletion, however, was made in a hybrid cell line [27],
corresponding to the proerythroblast stage, which was described
earlier (Figure 1). Thus, depending on the timing when the
deletion was made (ES cells, i.e., prior to development versus
proerythroblats, i.e., after differentiation), different results can be
found [102]. Interestingly, the level of transcription in the absence
of MCS-R2 was similar, and therefore the increased level of
transcription might not be the cause of PcG eviction. Also, the fact
that PcG eviction is associated with the recruitment of a
H3K27me3 demethylase suggests that it is more likely to be an
active process [73]. It is therefore possible that enhancers could
also recruit enzymes that remove histone modifications generated
by PcG complexes at the target promoter after chromosomal
looping, as it was suggested for the PIC. JMJD3 enrichment is not
detected at MCS-R2 in humanized mouse erythroid cells by
ChIP-qPCR, although this is at a much lower resolution [73].
However, ChIP-Seq studies showed enrichment of JMJD3 at both
genes and distal intergenic regions [103,104]. The role of remote
enhancers in the eviction of repressive PRC2 and PRC1 is also
supported by other recent studies [105–107].
This all together led to the conclusion that MCS-R2 has
multiple roles, and these may be applicable to any other enhancer:
recruitment of PolII and key TFs at the promoter, formation of a
looped structure involving several remote regulatory elements, and
the removal of repressive complexes such as PcG (Figure 5). It thus
seems that enhancers have evolved with the overall complexity of
mammalian transcription regulation by developing multiple roles
required for optimal gene expression. These different roles might
be allocated to different enhancers controlling the same gene;
some might be important for initiation of gene expression, others
for its maintenance. How to disentangle these roles remains a
challenge, since most of the time many events occur at the same
time during differentiation. Alternative models allowing short
kinetics (e.g., lipopolysaccharide (LPS)-activated macrophages
[108]) might be more suitable for the study of gene activation
when applicable. Indeed, the latest reflects gene activation in a
given cell type that is under a physiologic change, whereas globin
genes activation occurs with a change of cell identity during
differentiation.
Future Directions
Over the last five years, high-throughput sequencing technology
has been used to characterise human genetic diseases using
materials from patients but also has provided a very broad picture
of the chromatin landscape in many cell types. However,
functional analyses are still required to provide mechanistic
insights about enhancer functions. Over the last 30 years, single-
locus dissection such as what has been achieved at the a- and b-
globin loci remains a good example of where human genetics and
genetic engineering in the mouse can provide important answers
on how mammalian genes are regulated during differentiation and
development. This is also applicable to other loci. For example,
studies on patients with preaxial polydactyly led to the identifica-
tion of the regulatory element controlling the expression of sonic
hedgehog (SHH) in the posterior part of the limb [109].
Identifying individuals with a-thalassaemia by regular screenings
allowed the mapping of all the known mutations, but sometimes
new rare variants can be found, and these can provide new
mechanisms underlying human genetic disease [21]. Human
genetics, although powerful, still adds a layer of complexity when
genetic variability between individuals has to be taken into
account. Recently, a few rare cases of patients homozygous for
MCS-R2 deletion have been described [110,111]. Surprisingly,
these patients present a phenotype less severe than expected, even
with a broader deletion removing the other remote regulatory
elements on one chromosome [110]. This demonstrates that the
other regulatory elements must have a role but also suggests that,
when deleted, ‘‘orphan’’ enhancers might relay for a-globin
expression as recently suggested for other genes (enhancer
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adoption [112]). It is worth noting that in humans another
enhancer-like element has been found outside the region of
conserved synteny, 400 kb downstream from the a-globin locus
[58]. This element lies inside the intron of another host gene called
NME4, which is up-regulated in erythroid cells through an
alternative start site, as is the case for the upstream NPRL3 gene
[58,113]. Would this element take an important role when the
others are missing? This is a difficult question to address, since this
gene lies on another chromosome in the mouse and therefore no
suitable model to test this hypothesis is currently available.
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